Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
24.81
+0.73 (3.03%)
At close: Sep 12, 2025, 4:00 PM EDT
24.16
-0.65 (-2.62%)
After-hours: Sep 12, 2025, 5:19 PM EDT
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $17.26M in the quarter ending June 30, 2025, with 217.71% growth. This brings the company's revenue in the last twelve months to $23.93M, up 264.86% year-over-year. In the year 2024, Sol-Gel Technologies had annual revenue of $11.54M with 642.47% growth.
Revenue (ttm)
$23.93M
Revenue Growth
+264.86%
P/S Ratio
2.89
Revenue / Employee
$703,853
Employees
34
Market Cap
69.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.54M | 9.98M | 642.47% |
Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SLGL News
- 4 weeks ago - Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Sol-Gel Reports First Quarter 2025 Results - GlobeNewsWire
- 4 months ago - Sol-Gel Announces Reverse Share Split - GlobeNewsWire
- 5 months ago - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - GlobeNewsWire
- 5 months ago - Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis - GlobeNewsWire
- 10 months ago - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 1 year ago - UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 1 year ago - Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire